Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Mylan Reaffirms FY13 Adj. EPS View - Quick Facts

Mylan Inc. (MYL: Quote) provided its financial guidance for 2012, reaffirmed its growth targets for 2013, and outlined the key drivers for the company's continued long-term growth beyond 2013.

Mylan provided 2012 financial guidance that includes adjusted diluted earnings per share of between $2.30 and $2.50, and which would represent 18% growth over 2011 at the midpoint of the range. The company's guidance range for 2012 revenue is $6.8 billion to $7.2 billion, representing 14% annual growth at the midpoint of the range.

Analysts polled by Thomson Reuters expect the company to report earnings of $2.41 per share on revenues of $6.87 billion for fiscal 2012. Analysts' estimates typically exclude special items.

Mylan reaffirmed its target of $2.75 of adjusted earnings per share in 2013, representing annual growth of 15% (from the midpoint of its 2012 range), and updated its 2013 revenue target to $7.5 billion.

Mylan said that it will continue to invest significantly in its existing platform and from 2013 through 2016 expects to spend an additional $2.0 billion in research and development and $1.4 billion on capital expenditures, while increasing its annual manufacturing capacity to in excess of 82 billion doses.

In 2012, Mylan expects to market over 4,700 products and this number is expected to increase to over 6,700 products by 2015.

Mylan is currently targeting adjusted earnings per share of $6.00 in 2018, with opportunities already in house.

Register
To receive FREE breaking news email alerts for Mylan Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Proctor and Gamble (PG) has sold two of its soap brands to European consumer products giant Unilever (UN). Cincinnati-based P&G says the sale includes the global Camay brand, the Zest brand outside of North America and its Talisman manufacturing plant in Mexico. The plant employs approximately... Dish Network is no longer carrying Fox News in yet another dispute for the television provider. Fox News, which changed the face of cable news with its ardent advocacy of conservative issues, went dark Sunday, replaced on Dish by The Blaze, Glen Beck's new right-leaning channel. Fox Business channel... Swiss drug maker Roche Holding said a late-stage trial of its breast cancer drug Kadcyla did not provide superior results compared with an existing therapy.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.